Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells
1999
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer Statistics, 2021
2021 Standout
Advances in stem cell mobilization
2014
Asymmetric Methylation in the Hypermethylated CpG Promoter Region of the Human L1 Retrotransposon
1997
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
2003
CD44: From adhesion molecules to signalling regulators
2003 Standout
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
2003
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia
1999
DNA methylation patterns and epigenetic memory
2002 Standout
Neutrophils at work
2014 Standout
Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia
1991
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
1998
Advances in stem cell mobilization
2012
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 Standout
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche
2007 Standout
Diagnosis and management of refractoriness to platelet transfusion
2001
Cancer Statistics, 2006
2006 Standout
Randomized phase II study of biweekly CHOP anddose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505
2002
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial
2001
Transfusion Medicine — Blood Transfusion
1999 Standout
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Molecular mechanisms of cisplatin resistance
2011 Standout
Acute myeloid leukaemia
2006
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
2011 Standout
Targeting multidrug resistance in cancer
2006 Standout
The biology of the P-glycoproteins
1995
Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia
2003
The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia
1997
Platelets and the immune continuum
2011 Standout
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
2010 StandoutNature
The evaluation and management of platelet refractoriness and alloimmunization
2000
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger
2002
Intravenous antibiotics reduce the presence ofAspergillusin adult cystic fibrosis sputum
2013
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995)
2004
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
2004
Disseminated Intravascular Coagulation
1999 Standout
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
1997
Acute Myeloid Leukemia
1999
Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis
2003
Cancer as an evolutionary and ecological process
2006 Standout
Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma
2008
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Overview of Platelet Transfusion
2010
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
2003 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
1998
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells
2005
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Acute Myeloid Leukemia
2015 Standout
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
2015
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group
2003
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
1996 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Leukocyte Reduction and Ultraviolet B Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet Transfusions
1997
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
1999
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Biologic effects of leukocytes present in transfused cellular blood products
1994
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
High‐dose cytosine arabinoside in the treatment of acute myeloid leukemia
2006
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
1997
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Toward the potential cure of leukemias in the next decade
2018
Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission
2003
Cancer treatment and survivorship statistics, 2016
2016 Standout
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia
2006
Cancer treatment and survivorship statistics, 2019
2019 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
2005
A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
1998 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
A mini-review on platelet refractoriness.
2005
Adult acute myeloid leukaemia: update on treatment
1999
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
2002
Risks, Costs, and Alternatives to Platelet Transfusions
1999
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Coexistence of Quiescent and Active Adult Stem Cells in Mammals
2010 StandoutScience
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
2013
Works of M. Wolf being referenced
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
2014
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator
2008
Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
1994
The definition of refractoriness to platelet transfusions
1992
Factors influencing 20‐hour increments after platelet transfusion
1991
A Phase I/II Study of Intensive Dose Escalation of Cytarabine in Combination with Idarubicin and Etoposide in Induction and Consolidation Treatment of Adult Acute Myeloid Leukemia
1999
Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients
1999
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy
2002
Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts
2002
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors
1999
Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma
1992
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
1996
Clinical factors influencing the efficacy of pooled platelet transfusions
1988